Literature DB >> 17418056

Pancreatic enzyme therapy for pancreatic exocrine insufficiency.

J Enrique Domínguez-Muñoz1.   

Abstract

Pancreatic exocrine insufficiency with steatorrhea is a major consequence of pancreatic diseases (eg, chronic pancreatitis, cystic fibrosis, severe acute necrotizing pancreatitis, pancreatic cancer), extrapancreatic diseases such as celiac disease and Crohn's disease, and gastrointestinal and pancreatic surgical resection. Recognition of this entity is highly relevant to avoid malnutrition-related morbidity and mortality. Therapy for pancreatic exocrine insufficiency is based on the oral administration of pancreatic enzymes aiming at providing the duodenal lumen with sufficient active lipase at the time of gastric emptying of nutrients. Administration of enzymes in the form of enteric-coated minimicrospheres avoids acid-mediated lipase inactivation and ensures gastric emptying of enzymes in parallel with nutrients. Nevertheless, such factors as acidic intestinal pH and bacterial overgrowth may prevent normalization of fat digestion even in compliant patients. The present article critically reviews current therapeutic approaches to pancreatic exocrine insufficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418056     DOI: 10.1007/s11894-007-0005-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  45 in total

1.  Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules.

Authors:  E P DiMagno; J R Malagelada; V L Go; C G Moertel
Journal:  N Engl J Med       Date:  1977-06-09       Impact factor: 91.245

2.  Hydrogen breath test with glucose in exocrine pancreatic insufficiency.

Authors:  F Casellas; L Guarner; E Vaquero; M Antolín; X de Gracia; J R Malagelada
Journal:  Pancreas       Date:  1998-05       Impact factor: 3.327

3.  A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency.

Authors:  U Halm; C Löser; M Löhr; M Katschinski; J Mössner
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

4.  Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation.

Authors:  R J Stead; I Skypala; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

5.  A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.

Authors:  R C Stern; J D Eisenberg; J S Wagener; R Ahrens; M Rock; G doPico; D M Orenstein
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals.

Authors:  F Carrière; C Renou; V Lopez; J De Caro; F Ferrato; H Lengsfeld; A De Caro; R Laugier; R Verger
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

7.  Which is a less invasive pancreatic head resection: PD, PPPD, or DPPHR?

Authors:  K Yamaguchi; K Yokohata; K Nakano; K Ohtani; Y Ogawa; K Chijiiwa; M Tanaka
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

8.  Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.

Authors:  M J Bruno; E A Rauws; F J Hoek; G N Tytgat
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

9.  13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis.

Authors:  J Enrique Domínguez-Muñoz; Julio Iglesias-García; María Vilariño-Insua; Marta Iglesias-Rey
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04       Impact factor: 11.382

10.  Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis.

Authors:  A Carroccio; F Pardo; G Montalto; L Iapichino; M Soresi; M R Averna; G Iacono; A Notarbartolo
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

View more
  30 in total

1.  Diagnosing exocrine pancreatic insufficiency after surgery: when and which patients to treat.

Authors:  Helmut Friess; Christoph W Michalski
Journal:  HPB (Oxford)       Date:  2009-12       Impact factor: 3.647

2.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

3.  Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion.

Authors:  J Khasawneh; M D Schulz; A Walch; J Rozman; M Hrabe de Angelis; M Klingenspor; A Buck; M Schwaiger; D Saur; R M Schmid; G Klöppel; B Sipos; F R Greten; M C Arkan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

4.  Pancreatic enzyme therapy for pancreatic exocrine insufficiency.

Authors:  J Enrique Domínguez-Muñoz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-06

5.  How to manage: patient with a low faecal elastase.

Authors:  Kwan Wai Lam; John Leeds
Journal:  Frontline Gastroenterol       Date:  2019-11-15

6.  Assessment of Exocrine Function of Pancreas Following Pancreaticoduodenectomy.

Authors:  Kiran Thogari; Mallika Tewari; S K Shukla; S P Mishra; H S Shukla
Journal:  Indian J Surg Oncol       Date:  2019-03-18

7.  Central pancreatectomy without anastomosis.

Authors:  Michael Wayne; Siyamek Neragi-Miandoab; Franklin Kasmin; William Brown; Anil Pahuja; Avram M Cooperman
Journal:  World J Surg Oncol       Date:  2009-08-31       Impact factor: 2.754

8.  Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Authors:  Geng Zhang; Peijun He; Hanson Tan; Anuradha Budhu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Clin Cancer Res       Date:  2013-08-05       Impact factor: 12.531

9.  A proposal for a new clinical classification of chronic pancreatitis.

Authors:  Markus W Büchler; Marc E Martignoni; Helmut Friess; Peter Malfertheiner
Journal:  BMC Gastroenterol       Date:  2009-12-14       Impact factor: 3.067

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.